ReviewNature reviews. Nephrology2014
Nephrotoxic effects of designer drugs: synthetic is not better!
Review in Nature reviews. Nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Systematic review of nephrotoxicity of drugs of abuse, 2005-2016.BMC nephrology · 2017Pooled it
- Biopsy-proven Crescentic Glomerulonephritis Following Inhaled Methamphetamine Use: An Exceptional Case of Confirmed Drug-induced Glomerular Injury.Kidney medicine · 2025Article
- The effects of methamphetamine intoxication on acute kidney injury in Iraqi male addicts.Toxicology reports · 2025Article
- Field-Portable Technology for Illicit Drug Discrimination via Deep Learning of Hybridized Reflectance/Fluorescence Spectroscopic Fingerprints.Analytical chemistry · 2025Article
- New Synthetic Compounds with Psychoactive Action-Preliminary Results Among Primary and High School Students on the Territory of Novi Sad.Medicines (Basel, Switzerland) · 2025Article
- In vivo assessment of the nephrotoxic effects of the synthetic cannabinoid AB-FUBINACA.Forensic toxicology · 2025Article
- Methamphetamine use associated with gun and knife violence: A matched cohort analysis.Surgery open science · 2023Article
- Cannabinoid Signaling in Kidney Disease.Cells · 2023Review
- Synthetic cannabinoid-associated acute interstitial nephritis: An emerging cause of pediatric acute kidney injury?Clinical nephrology. Case studies · 2023Article
- Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.Biomedicines · 2022Review
- Cat on a hot tin roof (a nephrology zebra).Journal of nephrology · 2021Article
- The nephrologist's guide to cannabis and cannabinoids.Current opinion in nephrology and hypertension · 2020Review
- Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.Journal of the American Chemical Society · 2019Article
- Development of an in silico prediction model for chemical-induced urinary tract toxicity by using naïve Bayes classifier.Molecular diversity · 2019Article
- Pharmacology behind Common Drug Nephrotoxicities.Clinical journal of the American Society of Nephrology : CJASN · 2018Review
- Rhabdomyolysis observed at forensic autopsy: a series of 52 cases.Forensic science, medicine, and pathology · 2018Article
- Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.Drug and alcohol dependence · 2018Article
- Synthetic Pot: Not Your Grandfather's Marijuana.Trends in pharmacological sciences · 2017Review
- Novel psychoactive substances of interest for psychiatry.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Designer drugs are synthetic, psychoactive substances with similar structures and activity to existing scheduled drugs or controlled chemical compounds. The use of these drugs is not generally considered illegal and they cannot be detected using standard toxicology tests--essentially they are considered to be 'legal highs'. Over the past several years, increasing numbers of designer drugs have become available. These drugs are classified as amphetamine derivatives, phenylpiperazine derivatives, synthetic cathinones, synthetic cannabinoids, phencyclidine derivatives and synthetic opioids. Although euphoria is the desired effect, neuropsychiatric and cardiac manifestations are frequently observed in individuals using these drugs at high doses or using drugs that are contaminated with other substances. Some designer drugs are also associated with adverse renal effects, including acute kidney injury from pigment nephropathy, acute tubular necrosis, obstructive nephropathy and hyponatraemia. The misuse of these drugs should be recognized and clinicians made aware of the potential for acute nephrotoxicity as the health burden of these compounds increases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.